David Feder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Feder has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Luiz Affonso Fonseca
Clinical Analysis Laboratory, Centro Universitário FMABC, Santo André, Brazil
10 shared publications Fernando Luiz Affonso Fonseca
Laboratório de Análises Clínicas do Centro Universitário FMABC, Av. Lauro Gomes, 2000, CEP 09060-870, Santo André, SP, Brazil; Instituto de Ciências Farmacêuticas da Universidade Federal de São Paulo, Rua Prof. Artur Riedel, 275, 09972-270, Diadema, SP, Brazil
4 shared publicationsAlzira Alves de Siqueira Carvalho
Neurosciences Department, Faculdade de Medicina do ABC, Santo André, SP, Brazil
3 shared publications- Alzira Alves de Siqueira Carvalho
Neurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil
3 shared publications - Beatriz da Costa Aguiar Alves
Laboratório de Análises Clínicas, Centro Universitário FMABC, Santo André 09060-870, Brazil
3 shared publications - Edimar Cristiano Pereira
Department of Pharmaceutical Sciences, Federal University of Sao Paulo, Diadema 09913-030, SP, Brazil
3 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (12) , 001-008
Tiny molecules, mighty impacts: MicroRNAs in muscular dystrophies and myopathies
Microribonucleic acids (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally and play essential roles in muscle differentiation, regeneration, and metabolism. A specific subset, known as myomiRs, is predominantly expressed in muscle tissue and has been implicated in key molecular pathways underlying muscular dystrophies and myopathies. Due to their stability in biological fluids, myomiRs have emerged as non-invasive biomarkers. The present narrative review summarizes selected studies addressing myomiR expression patterns, functional roles, and translational implications in muscular dystrophies and myopathies, particularly Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), limb-girdle muscular dystrophy (LGMD), McArdle disease, and myofibrillar myopathy (MFM), highlighting their biological relevance and clinical potential. The available evidence indicates that myomiRs such as miR-1, miR-133a/b, miR-206, miR-29b, miR-31, and miR-486 are differentially expressed across these disorders and are involved in processes including muscle degeneration, regeneration, fibrosis, and inflammation. In DMD, several myomiRs are upregulated, reflecting ongoing muscle damage and regenerative activity, whereas in DM1, downregulation of miR-1, miR-133a/b, and miR-29b contributes to impaired muscle maturation and fibrosis. In contrast, miR-206 appears increased as part of a regenerative response, whereas miR-223–3p may reflect inflammatory activity or muscle damage. Evidence for McArdle disease remains scarce, underscoring the need for further investigation. In conclusion, understanding miRNA signatures may facilitate earlier diagnosis, disease stratification, and the development of targeted therapies in muscular dystrophies and myopathies.
- 6 October 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (12) , 001-008
Open AccessTiny molecules, mighty impacts: MicroRNAs in muscular dystrophies and myopathies
Microribonucleic acids (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally and play essential roles in muscle differentiation, regeneration, and metabolism. A specific subset, known as myomiRs, is predominantly expressed in muscle tissue and has been implicated in key molecular pathways underlying muscular dystrophies and myopathies. Due to their stability in biological fluids, myomiRs have emerged as non-invasive biomarkers. The present narrative review summarizes selected studies addressing myomiR expression patterns, functional roles, and translational implications in muscular dystrophies and myopathies, particularly Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), limb-girdle muscular dystrophy (LGMD), McArdle disease, and myofibrillar myopathy (MFM), highlighting their biological relevance and clinical potential. The available evidence indicates that myomiRs such as miR-1, miR-133a/b, miR-206, miR-29b, miR-31, and miR-486 are differentially expressed across these disorders and are involved in processes including muscle degeneration, regeneration, fibrosis, and inflammation. In DMD, several myomiRs are upregulated, reflecting ongoing muscle damage and regenerative activity, whereas in DM1, downregulation of miR-1, miR-133a/b, and miR-29b contributes to impaired muscle maturation and fibrosis. In contrast, miR-206 appears increased as part of a regenerative response, whereas miR-223–3p may reflect inflammatory activity or muscle damage. Evidence for McArdle disease remains scarce, underscoring the need for further investigation. In conclusion, understanding miRNA signatures may facilitate earlier diagnosis, disease stratification, and the development of targeted therapies in muscular dystrophies and myopathies.
- Open Access
- 28 November 2025
- Published by Faculdade de Filosofia e Ciências in Journal of Human Growth and Development
- Vol. 35 (03) , 486-493
Effects of vitamin D administration on mice muscle strength
Introduction: Vitamin D is characterized by a group of secosteroid molecules derived from 7-dehydrocholesterol (7-DHC). Its role in bone metabolism is well established; however, the mechanisms by which it may influence the musculoskeletal system, particularly in increasing muscle strength and mass, are still under investigation. Objective: To evaluate the impact of vitamin D supplementation on muscle strength in BALB/c mice over different supplementation periods. Methods: Twenty-four BALB/c mice were equally divided into 4 groups: Control (C), 7-day supplementation (7D), 15-day supplementation (15D), and 30-day supplementation (30D), with a fixed dose of 400 IU/day. Muscle strength was measured daily using the inverted grid method. At the end of each treatment period, blood and diaphragm muscle samples were collected to determine AST, ALT, urea, creatinine, CPK, and vitamin D levels. The diaphragm muscle was collected to measure the cross-sectional area, as well as the major and minor diameters. Results: Vitamin D supplementation for 15 days caused a significant reduction in blood glucose levels compared to the 7D group (p<0.05). Regarding vitamin D levels, the supplemented groups showed significantly higher values compared to the control group. The diaphragm area of mice supplemented for 15 days was larger compared to the control group. Conclusion: Vitamin D does not affect muscle strength, regardless of the supplementation period. Moreover, it does not cause hepatotoxic or nephrotoxic effects. However, the supplementation of BALB/c mice with vitamin D for 15 days may reduce glucose levels and increase diaphragm area.
- 28 November 2025
- Published by Faculdade de Filosofia e Ciências in Journal of Human Growth and Development
- Vol. 35 (03) , 486-493
Open AccessEffects of vitamin D administration on mice muscle strength
Introduction: Vitamin D is characterized by a group of secosteroid molecules derived from 7-dehydrocholesterol (7-DHC). Its role in bone metabolism is well established; however, the mechanisms by which it may influence the musculoskeletal system, particularly in increasing muscle strength and mass, are still under investigation. Objective: To evaluate the impact of vitamin D supplementation on muscle strength in BALB/c mice over different supplementation periods. Methods: Twenty-four BALB/c mice were equally divided into 4 groups: Control (C), 7-day supplementation (7D), 15-day supplementation (15D), and 30-day supplementation (30D), with a fixed dose of 400 IU/day. Muscle strength was measured daily using the inverted grid method. At the end of each treatment period, blood and diaphragm muscle samples were collected to determine AST, ALT, urea, creatinine, CPK, and vitamin D levels. The diaphragm muscle was collected to measure the cross-sectional area, as well as the major and minor diameters. Results: Vitamin D supplementation for 15 days caused a significant reduction in blood glucose levels compared to the 7D group (p<0.05). Regarding vitamin D levels, the supplemented groups showed significantly higher values compared to the control group. The diaphragm area of mice supplemented for 15 days was larger compared to the control group. Conclusion: Vitamin D does not affect muscle strength, regardless of the supplementation period. Moreover, it does not cause hepatotoxic or nephrotoxic effects. However, the supplementation of BALB/c mice with vitamin D for 15 days may reduce glucose levels and increase diaphragm area.
- 13 March 2024
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 105 (2) , 75-85
Trilobatin contributes to the improvement of myopathy in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) occurs due to genetic mutations that lead to a deficiency in dystrophin production and consequent progressive degeneration of skeletal muscle fibres, through oxidative stress and an exacerbated inflammatory process. The flavonoid trilobatin (TLB) demonstrates antioxidant and anti-inflammatory potential. Its high safety profile and effective action make it a potent therapy for the process of dystrophic muscle myonecrosis. Thus, we sought to investigate the action of TLB on damage in a DMD model, the mdx mouse. Eight-week-old male animals were treated with 160 mg/kg/day of trilobatin for 8 weeks. Control animals were treated with saline. Following treatment, muscle strength, serum creatine kinase (CK) levels, histopathology (necrotic myofibres, regenerated fibres/central nuclei, Feret's diameter and inflammatory area) and the levels of catalase and NF-kappa B (western blotting) of the quadriceps (QUA), diaphragm (DIA) and tibialis anterior (TA) muscles were measured. TLB was able to significantly increase muscle strength and reduce serum CK levels in dystrophic animals. The QUA of mdx mice showed a reduction in catalase and the number of fibres with a centralized nucleus after treatment with TLB. In the DIA of dystrophic animals, TLB reduced the necrotic myofibres, inflammatory area and NF-kappa B and increased the number of regenerated fibres and the total fibre diameter. In TA, TLB increased the number of regenerated fibres and reduced catalase levels in these animals. It is concluded that in the mdx experimental model, treatment with TLB was beneficial in the treatment of DMD.
- 13 March 2024
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 105 (2) , 75-85
Trilobatin contributes to the improvement of myopathy in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) occurs due to genetic mutations that lead to a deficiency in dystrophin production and consequent progressive degeneration of skeletal muscle fibres, through oxidative stress and an exacerbated inflammatory process. The flavonoid trilobatin (TLB) demonstrates antioxidant and anti-inflammatory potential. Its high safety profile and effective action make it a potent therapy for the process of dystrophic muscle myonecrosis. Thus, we sought to investigate the action of TLB on damage in a DMD model, the mdx mouse. Eight-week-old male animals were treated with 160 mg/kg/day of trilobatin for 8 weeks. Control animals were treated with saline. Following treatment, muscle strength, serum creatine kinase (CK) levels, histopathology (necrotic myofibres, regenerated fibres/central nuclei, Feret's diameter and inflammatory area) and the levels of catalase and NF-kappa B (western blotting) of the quadriceps (QUA), diaphragm (DIA) and tibialis anterior (TA) muscles were measured. TLB was able to significantly increase muscle strength and reduce serum CK levels in dystrophic animals. The QUA of mdx mice showed a reduction in catalase and the number of fibres with a centralized nucleus after treatment with TLB. In the DIA of dystrophic animals, TLB reduced the necrotic myofibres, inflammatory area and NF-kappa B and increased the number of regenerated fibres and the total fibre diameter. In TA, TLB increased the number of regenerated fibres and reduced catalase levels in these animals. It is concluded that in the mdx experimental model, treatment with TLB was beneficial in the treatment of DMD.
- Open Access
- 23 March 2023
- Published by Universidade do Contestado - UnC in Saúde e meio ambiente: revista interdisciplinar
- Vol. 12, 31-63
potencial uso do riluzole no tratamento do câncer
O riluzole tem sido usado para o tratamento da Esclerose Lateral Amiotrófica (ELA). Estudos experimentais têm mostrado inibição do crescimento tumoral com riluzole. O objetivo desta revisão sistemática foi analisar as potencialidades do tratamento de cânceres com uso de riluzole. Foram investigadas publicações científicas nas bases Web of Science, Scopus e Pubmed de 2007 a 2021 com os termos câncer e riluzole. A discussão mostra a relação do glutamato com o câncer e como o riluzole atua como um importante inibidor da sinalização deste componente relacionado com a taxa de crescimento e invasibilidade de tipos específicos de câncer. A maioria dos diferentes estudos in vitro, in vivo ou em humanos relata que o riluzole tem se apresentado como uma droga promissora no tratamento de tipos específicos de câncer. No entanto, mais pesquisas tornam-se necessárias antes de conclusões definitivas sobre o uso de riluzole para diversos tipos de câncer. Palavras-chave: Neoplasias; Riluzole.
- 23 March 2023
- Published by Universidade do Contestado - UnC in Saúde e meio ambiente: revista interdisciplinar
- Vol. 12, 31-63
Open Accesspotencial uso do riluzole no tratamento do câncer
O riluzole tem sido usado para o tratamento da Esclerose Lateral Amiotrófica (ELA). Estudos experimentais têm mostrado inibição do crescimento tumoral com riluzole. O objetivo desta revisão sistemática foi analisar as potencialidades do tratamento de cânceres com uso de riluzole. Foram investigadas publicações científicas nas bases Web of Science, Scopus e Pubmed de 2007 a 2021 com os termos câncer e riluzole. A discussão mostra a relação do glutamato com o câncer e como o riluzole atua como um importante inibidor da sinalização deste componente relacionado com a taxa de crescimento e invasibilidade de tipos específicos de câncer. A maioria dos diferentes estudos in vitro, in vivo ou em humanos relata que o riluzole tem se apresentado como uma droga promissora no tratamento de tipos específicos de câncer. No entanto, mais pesquisas tornam-se necessárias antes de conclusões definitivas sobre o uso de riluzole para diversos tipos de câncer. Palavras-chave: Neoplasias; Riluzole.
- 1 September 2022
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 25 (9) , 918-923
Comparative Study on the Effects of Paullinia cupana , PC-18 and Magnesium Chloride on Solid Ehrlich Tumor
New perspectives arise in the therapeutic practice for cancer, with the objective to not only treat patients, but also improve their quality of life. Guarana, a plant from Brazilian Amazon presents a wide range of pharmacological actions. This study evaluated the effect of Guarana (Paullinia cupana) extract, pure and dry Guarana (PC-18) extract and magnesium chloride (MgCl2) in mice of the Balb/c strain inoculated with the Ehrlich tumor regarding gene expression of inflammatory markers transforming growth factor-β1 and tumor necrosis factor alpha and oxidative stress (OS) and fatigue, superoxide dismutase, catalase, and glutathione peroxidase 4 and analyzed myelotoxicity and hepatotoxicity. After euthanasia, blood was collected to analyze the complete blood count and measured the levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase). Hepatoprotective actions of the crude extract of P. cupana and PC-18 extract were noticed. The PC-18 and MgCl2 group showed the best result regarding animal welfare. There were no associations between compounds and gene expression regarding fatigue and OS. PC-18 reduced the tumor and may have an antitumor action. The crude extract of Guarana presented hepatoprotective action.
- 1 September 2022
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 25 (9) , 918-923
Comparative Study on the Effects of Paullinia cupana , PC-18 and Magnesium Chloride on Solid Ehrlich Tumor
New perspectives arise in the therapeutic practice for cancer, with the objective to not only treat patients, but also improve their quality of life. Guarana, a plant from Brazilian Amazon presents a wide range of pharmacological actions. This study evaluated the effect of Guarana (Paullinia cupana) extract, pure and dry Guarana (PC-18) extract and magnesium chloride (MgCl2) in mice of the Balb/c strain inoculated with the Ehrlich tumor regarding gene expression of inflammatory markers transforming growth factor-β1 and tumor necrosis factor alpha and oxidative stress (OS) and fatigue, superoxide dismutase, catalase, and glutathione peroxidase 4 and analyzed myelotoxicity and hepatotoxicity. After euthanasia, blood was collected to analyze the complete blood count and measured the levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase). Hepatoprotective actions of the crude extract of P. cupana and PC-18 extract were noticed. The PC-18 and MgCl2 group showed the best result regarding animal welfare. There were no associations between compounds and gene expression regarding fatigue and OS. PC-18 reduced the tumor and may have an antitumor action. The crude extract of Guarana presented hepatoprotective action.
- Open Access
- 1 November 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (11) , 1503-1508
Effects of nasal aspiration by the Proetz® method in pediatric patients with sinusitis
SUMMARY OBJECTIVE: To characterize the effects of nasal aspiration with Proetz® in peak nasal inspiratory flow (PNIF) in pediatric sinusitis (PS) patients with nasal obstruction. METHODS: This is a non-randomized descriptive-analytical clinical trial with a quantitative approach. The sample comprised 30 children. Initially, the PNIF was measured and the Visual Analogical Scale (VAS) was used for nasal obstruction, followed by the nasal aspiration procedure. The SNOT-22 questionnaire was applied to the legal guardian of each child, and one week later, it was reapplied for the sake of follow-up. RESULTS: 16 (53.3%) patients were females and 14 (46.7%) were males, with an average age of 6.4±1.8 years (between 4 and 10 years of age). Analyses of the VAS for obstruction before the intervention revealed that 10 of the participants (33.3%) presented moderate levels, and 20 of them (66.7%) severe levels. However, after the Proetz® method was applied, all the samples (n=30) had mild levels. The PNIF significantly increased after the technique was used, with an improvement of 23.4% in mean values. There was no significant correlation between the VAS and the PNIF. CONCLUSION: Nasal aspiration with the Proetz® method significantly improved the clinical condition of sinusitis patients with nasal obstruction according to the visual analogical scale, the PNIF, and the SNOT-22 questionnaire. No correlation between the VAS and the PNIF could be found. The study confirms the importance of non-pharmacological interventions in the treatment of sinusitis in children, thus resulting in an improvement in their quality of life.
- 1 November 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (11) , 1503-1508
Open AccessEffects of nasal aspiration by the Proetz® method in pediatric patients with sinusitis
SUMMARY OBJECTIVE: To characterize the effects of nasal aspiration with Proetz® in peak nasal inspiratory flow (PNIF) in pediatric sinusitis (PS) patients with nasal obstruction. METHODS: This is a non-randomized descriptive-analytical clinical trial with a quantitative approach. The sample comprised 30 children. Initially, the PNIF was measured and the Visual Analogical Scale (VAS) was used for nasal obstruction, followed by the nasal aspiration procedure. The SNOT-22 questionnaire was applied to the legal guardian of each child, and one week later, it was reapplied for the sake of follow-up. RESULTS: 16 (53.3%) patients were females and 14 (46.7%) were males, with an average age of 6.4±1.8 years (between 4 and 10 years of age). Analyses of the VAS for obstruction before the intervention revealed that 10 of the participants (33.3%) presented moderate levels, and 20 of them (66.7%) severe levels. However, after the Proetz® method was applied, all the samples (n=30) had mild levels. The PNIF significantly increased after the technique was used, with an improvement of 23.4% in mean values. There was no significant correlation between the VAS and the PNIF. CONCLUSION: Nasal aspiration with the Proetz® method significantly improved the clinical condition of sinusitis patients with nasal obstruction according to the visual analogical scale, the PNIF, and the SNOT-22 questionnaire. No correlation between the VAS and the PNIF could be found. The study confirms the importance of non-pharmacological interventions in the treatment of sinusitis in children, thus resulting in an improvement in their quality of life.
- Open Access
- 1 September 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 3149-3155
Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
Introduction: Diabetes mellitus (DM) stands out as one of the chronic diseases with the highest morbidity and mortality rates worldwide. Among the many complications of DM, diabetic retinopathy (DR) is one of the causes of blindness in patients aged between 20 and 64 years. At least 90% of the new cases showed to have the retinal structure and function restored when proper treatment was provided. Aim: To evaluate the efficacy of the antiangiogenic bevacizumab in the treatment of DR according not only to the clinical laboratory parameters for glycated hemoglobin (HbA1C) and capillary glycemia but also to the ophthalmological parameters for optical coherence tomography (OCT) and best-corrected visual acuity (BCVA). Patients and Methods: A total of 11 individuals were included and followed up for 12 months after 3 administrations of bevacizumab. Results: Upon associating the ophthalmological and laboratory variables throughout the treatment, no significant alterations could be seen regarding the analyzed variables. However, it was observed that HbA1c values and the total leukocyte count negatively interfered with the treatment response. Conclusion: The current study showed that HbA1c values and the amount of leukocytes negatively interfere with the therapeutic response. Therefore, laboratory analyses of these parameters are recommended for diabetic patients undergoing the above-mentioned treatment.
- 1 September 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 3149-3155
Open AccessEffects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
Introduction: Diabetes mellitus (DM) stands out as one of the chronic diseases with the highest morbidity and mortality rates worldwide. Among the many complications of DM, diabetic retinopathy (DR) is one of the causes of blindness in patients aged between 20 and 64 years. At least 90% of the new cases showed to have the retinal structure and function restored when proper treatment was provided. Aim: To evaluate the efficacy of the antiangiogenic bevacizumab in the treatment of DR according not only to the clinical laboratory parameters for glycated hemoglobin (HbA1C) and capillary glycemia but also to the ophthalmological parameters for optical coherence tomography (OCT) and best-corrected visual acuity (BCVA). Patients and Methods: A total of 11 individuals were included and followed up for 12 months after 3 administrations of bevacizumab. Results: Upon associating the ophthalmological and laboratory variables throughout the treatment, no significant alterations could be seen regarding the analyzed variables. However, it was observed that HbA1c values and the total leukocyte count negatively interfered with the treatment response. Conclusion: The current study showed that HbA1c values and the amount of leukocytes negatively interfere with the therapeutic response. Therefore, laboratory analyses of these parameters are recommended for diabetic patients undergoing the above-mentioned treatment.
- 28 August 2020
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 6 (6) , 346-353
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
- 28 August 2020
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 6 (6) , 346-353
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
- Open Access
- 15 July 2020
- Published by Society of Pharmaceutical Tecnocrats in Universal Journal of Pharmaceutical Research
PHYTOCHEMICAL PROFILE WITH ANTI-TUMOR ACTIVITY ESTIMATION OF CRUDE EXTRACT, ESSENTIAL OIL AND D-LIMONENE FROM CITRUS AURANTIUM L. AGAINST EHRLICH CARCINOMA
Objective: Plant based drugs have been a solution in the search for more cost-effective and less harmful drugs for the treatment of neoplasia. Citrus aurantium L. (Rutaceae) is abundant in Brazil and D-limonene, a monoterpene used in the prevention and treatment of neoplasia, was identified as a major compound in the oil of this specie. Objective of current study includes estimation of anti-tumor activity of Citrus aurantium L. (Rutaceae) (crude extract, essential oil and D-limonene) against Ehrlich carcinoma, as well as their phytochemical evaluation (D-limonene and essential oil). Methods: There was a randomized non-clinical trial in which were used adult male mice (Balb-C). Four groups of animals were used having 6 numbers of animal in each group. All groups were inoculated with the Ehrlich tumor and then received the treatment (control, crude extract, essential oil and D-limonene) by oral route daily (28 day treatment). Essential oil was obtained by hydro-distillation and analyzed by the means of GC (Gas Chromatography) that was attached to mass spectrometry. In last of the observations hemogram was obtained. Results: Animals treated with the essential oil has shown no significant difference compared to the group treated with D-limonene. The group treated with crude extract had a growth inhibition close to the essential oil and D-limonene groups. Conclusion: It´s concluded that the essential oil and the crude extract of Citrus aurantium, L. (Rutaceae) can become therapeutic agents because of their anti-tumor activity with no toxicity to the blood cells and have low cost of production. Further studies are necessary, so they can be used in the treatment of neoplasia in humans. The chromatographic and spectrometric analyzes indicated the presence of other components in smaller amounts in the essential oil, which suggests that they could have a synergic activity to the D-limonene. Peer Review History: Received 2 June 2020; Revised 25 June; Accepted 4 July, Available online 15 July 2020 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 8.0/10 Reviewer(s) detail: Name: Ahmad Najib Affiliation: Universitas Muslim Indonesia, Makassar, Indonesia E-mail: ahmad.najib@umi.ac.id Name: Dr. Mohamed Said Fathy Al-Refaey Affiliation: University of Sadat City, Menofia, Egypt E-mail: mido_ph212@yahoo.com Comments of reviewer(s): Similar Articles: CYTOTOXIC EFFECT AND PHYTOCHEMICAL STUDY OF PETROLEUM ETHER EXTRACT OF TILIA CORDATA MILL
- 15 July 2020
- Published by Society of Pharmaceutical Tecnocrats in Universal Journal of Pharmaceutical Research
Open AccessPHYTOCHEMICAL PROFILE WITH ANTI-TUMOR ACTIVITY ESTIMATION OF CRUDE EXTRACT, ESSENTIAL OIL AND D-LIMONENE FROM CITRUS AURANTIUM L. AGAINST EHRLICH CARCINOMA
Objective: Plant based drugs have been a solution in the search for more cost-effective and less harmful drugs for the treatment of neoplasia. Citrus aurantium L. (Rutaceae) is abundant in Brazil and D-limonene, a monoterpene used in the prevention and treatment of neoplasia, was identified as a major compound in the oil of this specie. Objective of current study includes estimation of anti-tumor activity of Citrus aurantium L. (Rutaceae) (crude extract, essential oil and D-limonene) against Ehrlich carcinoma, as well as their phytochemical evaluation (D-limonene and essential oil). Methods: There was a randomized non-clinical trial in which were used adult male mice (Balb-C). Four groups of animals were used having 6 numbers of animal in each group. All groups were inoculated with the Ehrlich tumor and then received the treatment (control, crude extract, essential oil and D-limonene) by oral route daily (28 day treatment). Essential oil was obtained by hydro-distillation and analyzed by the means of GC (Gas Chromatography) that was attached to mass spectrometry. In last of the observations hemogram was obtained. Results: Animals treated with the essential oil has shown no significant difference compared to the group treated with D-limonene. The group treated with crude extract had a growth inhibition close to the essential oil and D-limonene groups. Conclusion: It´s concluded that the essential oil and the crude extract of Citrus aurantium, L. (Rutaceae) can become therapeutic agents because of their anti-tumor activity with no toxicity to the blood cells and have low cost of production. Further studies are necessary, so they can be used in the treatment of neoplasia in humans. The chromatographic and spectrometric analyzes indicated the presence of other components in smaller amounts in the essential oil, which suggests that they could have a synergic activity to the D-limonene. Peer Review History: Received 2 June 2020; Revised 25 June; Accepted 4 July, Available online 15 July 2020 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 8.0/10 Reviewer(s) detail: Name: Ahmad Najib Affiliation: Universitas Muslim Indonesia, Makassar, Indonesia E-mail: ahmad.najib@umi.ac.id Name: Dr. Mohamed Said Fathy Al-Refaey Affiliation: University of Sadat City, Menofia, Egypt E-mail: mido_ph212@yahoo.com Comments of reviewer(s): Similar Articles: CYTOTOXIC EFFECT AND PHYTOCHEMICAL STUDY OF PETROLEUM ETHER EXTRACT OF TILIA CORDATA MILL
- Open Access
- 23 November 2019
- Published by Wiley in Parkinson's Disease
- Vol. 2019, 1-14
Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review
In the early sixties, a discussion started regarding the association between Parkinson’s disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and “in vitro” models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson’s symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.
- 23 November 2019
- Published by Wiley in Parkinson's Disease
- Vol. 2019, 1-14
Open AccessAnalysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review
In the early sixties, a discussion started regarding the association between Parkinson’s disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and “in vitro” models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson’s symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.